Bexion Pharmaceuticals doses first patient in new cancer clinical study
A Northern Kentucky startup developing targeted therapies for cancer has dosed its first patient in a clinical study being held in Cincinnati.
Covington-based Bexion Pharmaceuticals, a clinical-stage biopharma company, said Tuesday it dosed its first adult patient in the new study for BXQ-350, its lead drug candidate.
The study, known as RETRO, will assess the potential for BXQ-350 to reduce the intensity and/or duration of chemotherapy-induced peripheral neuropathy, or CIPN, a common side effect…
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Liz Engel Source Type: news
More News: Brain | Cancer | Cancer & Oncology | Chemotherapy | Health Management | Neurology | Peripheral Neuropathy | Study